Page 143 - NPPA full book

position in existing markets and looking towards future, Indian pharmaceutical industry will have to innovate and prepare

for potentially new disease classes, newer drugs, devices and pharma solutions. At the same time, sight should not be lost of
neglected tropical diseases (NTD) afflicting the developing countries like malaria, leishmaniasis, dengue and chikungunya, etc.,

where concerted research efforts would be required. Adoption of evolving technologies, powered by Artificial Intelligence

(AI), direct-to-consumer delivery models and convergence of drugs, devices and patient services will also be crucial as it will

allow the industry to leverage innovative means to make healthcare accessible and affordable to all individuals.

Continuing the Successful Run

The last three years have been pivotal for the Indian pharmaceutical sector with renewed focus on innovation, R&D; and launch

of schemes geared towards strengthening the manufacturing of pharmaceuticals’ as well as medical devices in the country.

The launch of the NIPER research portal containing information about research activities, patents filed etc., by the NIPERS
would be beneficial to all stakeholders and also facilitate industry-academia linkages.

The present trajectory

with strong foundations

is also a template for the
future pharmaceutical

industry of India. This will

be coupled by upgradation

to complex products, NCE/
NBE, Precision Medicine,

Cell and Gene Therapy,

drugs for Orphan and

Neglected Diseases, and
Anti-Microbial Resistance

(AMR). Drugs will also

be developed for India-

specific ailments.

Sun Pharma

133